Cure My Disease

Don't miss your cure!

 Log in / Sign up

Monthly migraine shot cuts headache days in asian patients

NCT ID NCT03867201

Completed Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 29 times

Summary

This study tested a monthly injection called erenumab in 557 Asian adults with chronic migraine (15+ headache days per month). Over 12 weeks, the drug reduced the number of migraine days compared to a placebo. The goal was to ease symptoms and improve daily life, not to cure migraines.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100000, China

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100039, China

  • Novartis Investigative Site

    Xiamen, Fujian, 361001, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510000, China

  • Novartis Investigative Site

    Shijiazhuang, Hebei, 500051, China

  • Novartis Investigative Site

    Zhengzhou, Henan, 450052, China

  • Novartis Investigative Site

    Jingzhou, Hubei, 434020, China

  • Novartis Investigative Site

    Wuhan, Hubei, 430060, China

  • Novartis Investigative Site

    Changsha, Hunan, 410003, China

  • Novartis Investigative Site

    Changsha, Hunan, 410008, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, 210008, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, 210029, China

  • Novartis Investigative Site

    Suzhou, Jiangsu, 215004, China

  • Novartis Investigative Site

    Wuxi, Jiangsu, 214002, China

  • Novartis Investigative Site

    Changchun, Jilin, 130021, China

  • Novartis Investigative Site

    Changchun, Jilin, 130041, China

  • Novartis Investigative Site

    Shenyang, Liaoning, 100016, China

  • Novartis Investigative Site

    Yinchuan, Ningxia, 100039, China

  • Novartis Investigative Site

    Jinan, Shandong, 250013, China

  • Novartis Investigative Site

    Xian, Shanxi, 710061, China

  • Novartis Investigative Site

    Chengdu, Sichuan, 610041, China

  • Novartis Investigative Site

    Kunming, Yunnan, 650000, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310006, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310016, China

  • Novartis Investigative Site

    Beijing, 065001, China

  • Novartis Investigative Site

    Beijing, 100050, China

  • Novartis Investigative Site

    Chongqing, 400016, China

  • Novartis Investigative Site

    Qingdao, 266000, China

  • Novartis Investigative Site

    Shanghai, 200040, China

  • Novartis Investigative Site

    Shanghai, 200080, China

  • Novartis Investigative Site

    Nashik, Maharashtra, 422005, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, 226014, India

  • Novartis Investigative Site

    Dehradun, Uttarakhand, 248001, India

  • Novartis Investigative Site

    Seberang Jaya, Pulau Pinang, 13700, Malaysia

  • Novartis Investigative Site

    Sungai Buloh, Selangor, 47000, Malaysia

  • Novartis Investigative Site

    Kuala Terengganu, Terengganu, 20400, Malaysia

  • Novartis Investigative Site

    Kuala Lumpur, 59100, Malaysia

  • Novartis Investigative Site

    Manila, National Capital Region, 1000, Philippines

  • Novartis Investigative Site

    Pasig, 1605, Philippines

  • Novartis Investigative Site

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    Hwaseong-si, Gyeonggi-do, 18450, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 08308, South Korea

  • Novartis Investigative Site

    Gyeonggi-do, 11765, South Korea

  • Novartis Investigative Site

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    Seoul, 03181, South Korea

  • Novartis Investigative Site

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    Seoul, 139-711, South Korea

  • Novartis Investigative Site

    Chiayi City, 60002, Taiwan

  • Novartis Investigative Site

    Taichung, 40447, Taiwan

  • Novartis Investigative Site

    Taichung County, 411743, Taiwan

  • Novartis Investigative Site

    Tainan, 701, Taiwan

  • Novartis Investigative Site

    Tainan, 71004, Taiwan

  • Novartis Investigative Site

    Taipei, 10449, Taiwan

  • Novartis Investigative Site

    Taipei, 11217, Taiwan

  • Novartis Investigative Site

    Taipei, 114, Taiwan

  • Novartis Investigative Site

    Taoyuan, 33305, Taiwan

  • Novartis Investigative Site

    Bangkok, THA, 10400, Thailand

  • Novartis Investigative Site

    Khon Kaen, THA, 40002, Thailand

  • Novartis Investigative Site

    Bangkok, 10330, Thailand

  • Novartis Investigative Site

    Bangkok, 10400, Thailand

  • Novartis Investigative Site

    Chiang Mai, 50200, Thailand

  • Novartis Investigative Site

    Ho Chi Minh City, VNM, 700000, Vietnam

  • Novartis Investigative Site

    Hanoi, 100000, Vietnam

Conditions

Explore the condition pages connected to this study.

MIGRAINE